ZWJ Investment Counsel’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $75.1M | Buy |
395,978
+8,717
| +2% | +$1.64M | 2.43% | 10 |
|
|
2026
Q1 | $76.4M | Buy |
387,261
+5,606
| +1% | +$1.08M | 2.75% | 8 |
|
|
2025
Q4 | $70.2M | Sell |
381,655
-3,986
| -1% | -$699K | 2.53% | 11 |
|
|
2025
Q3 | $59.2M | Buy |
385,641
+3,906
| +1% | +$591K | 2.09% | 15 |
|
|
2025
Q2 | $53.4M | Buy |
381,735
+7,075
| +2% | +$992K | 1.98% | 18 |
|
|
2025
Q1 | $55.1M | Buy |
374,660
+9,310
| +3% | +$1.35M | 2.24% | 15 |
|
|
2024
Q4 | $47.9M | Buy |
365,350
+37,264
| +11% | +$5.22M | 1.98% | 18 |
|
|
2024
Q3 | $51.1M | Buy |
328,086
+1,362
| +0.4% | +$220K | 2.09% | 14 |
|
|
2024
Q2 | $51M | Buy |
326,724
+4,278
| +1% | +$644K | 2.24% | 11 |
|
|
2024
Q1 | $43.7M | Buy |
322,446
+13,161
| +4% | +$1.74M | 1.99% | 18 |
|
|
2023
Q4 | $41.7M | Buy |
309,285
+279
| +0.1% | +$36.3K | 2.14% | 15 |
|
|
2023
Q3 | $41.9M | Buy |
+309,006
| New | +$42.2M | 2.32% | 12 |
|
|
2023
Q2 | – | Sell |
-320,392
| Closed | -$44.5M | – | 198 |
|
|
2023
Q1 | $44.5M | Sell |
320,392
-4,278
| -1% | -$576K | 2.45% | 8 |
|
|
2022
Q4 | $44M | Buy |
324,670
+2,684
| +0.8% | +$337K | 2.49% | 7 |
|
|
2022
Q3 | $35.3M | Sell |
321,986
-6,126
| -2% | -$777K | 2.22% | 10 |
|
|
2022
Q2 | $43.4M | Sell |
328,112
-3,566
| -1% | -$468K | 2.53% | 5 |
|
|
2022
Q1 | $44M | Buy |
331,678
+6,328
| +2% | +$759K | 2.33% | 10 |
|
|
2021
Q4 | $37.9M | Buy |
+325,350
| New | +$38.3M | 1.94% | 16 |
|
|
2021
Q3 | – | Sell |
-314,738
| Closed | -$37.7M | – | 176 |
|
|
2021
Q2 | $37.7M | Buy |
314,738
+9,199
| +3% | +$1.01M | 2.18% | 15 |
|
|
2021
Q1 | $30.4M | Buy |
305,539
+9,163
| +3% | +$921K | 1.87% | 17 |
|
|
2020
Q4 | $29.6M | Buy |
296,376
+5,048
| +2% | +$535K | 2.01% | 17 |
|
|
2020
Q3 | $31.9M | Sell |
291,328
-7,030
| -2% | -$782K | 2.56% | 11 |
|
|
2020
Q2 | $31.6M | Sell |
298,358
-61,733
| -17% | -$6.38M | 2.74% | 10 |
|
|
2020
Q1 | $32.2M | Buy |
360,091
+7,544
| +2% | +$710K | 2.87% | 4 |
|
|
2019
Q4 | $35.2M | Sell |
352,547
-15,975
| -4% | -$1.5M | 2.37% | 10 |
|
|
2019
Q3 | $32.9M | Buy |
368,522
+4,484
| +1% | +$389K | 2.56% | 7 |
|
|
2019
Q2 | $30.1M | Buy |
364,038
+57,431
| +19% | +$4.5M | 2.36% | 13 |
|
|
2019
Q1 | $24.8M | Buy |
306,607
+68,844
| +29% | +$5.43M | 2.04% | 20 |
|
|
2018
Q4 | $18.1M | Buy |
237,763
+33,621
| +16% | +$2.63M | 1.7% | 22 |
|
|
2018
Q3 | $16.2M | Buy |
204,142
+13,154
| +7% | +$995K | 1.31% | 35 |
|
|
2018
Q2 | $13.4M | Buy |
190,988
+88,720
| +87% | +$6.38M | 1.16% | 42 |
|
|
2018
Q1 | $7.15M | Buy |
102,268
+62,602
| +158% | +$4.34M | 0.64% | 50 |
|
|
2017
Q4 | $2.75M | Buy |
+39,666
| New | +$2.67M | 0.22% | 68 |
|
Other funds holding AZN
RG
CDDEC
BTCPP
AAMU
ISS
AIM
ZWJ Investment Counsel's AZN Position: Q2 2026 in Review
ZWJ Investment Counsel increased its AstraZeneca (AZN) stake by 2.3% in Q2 2026, buying an estimated $1.64M and bringing the position to 395,978 shares worth $75.1M. The position accounts for 2.43% of the portfolio, ranked #10.
ZWJ Investment Counsel first reported a position in AZN in Q4 2017 and has held it in 33 quarters since. The position peaked at $76.4M in Q1 2026. 655 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- ZWJ Investment Counsel held 395,978 shares of AstraZeneca worth $75.1M as of Q2 2026.
- ZWJ Investment Counsel bought 8,717 AstraZeneca shares in Q2 2026, an estimated $1.64M.
- AstraZeneca made up 2.43% of ZWJ Investment Counsel's portfolio in Q2 2026, its #10 holding.
- ZWJ Investment Counsel first reported a position in AstraZeneca in Q4 2017 and has held it in 33 quarters since.
- ZWJ Investment Counsel's AstraZeneca position peaked at $76.4M in Q1 2026.
- 655 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on ZWJ Investment Counsel's 13F filing for Q2 2026, filed 16 Jul 2026.